COPENHAGEN, Denmark, September 13, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today, that it has been awarded another contract valued at more than EUR 11 million to supply its MVA-BN® smallpox vaccine to rescEU, a strategic reserve within the European Union (EU). This order follows an initial contract awarded in June 2023 and is also for delivery in 2024.

丹麦哥本哈根，2023年9月13日-巴伐利亚北欧A/S（OMX:BAVA）今天宣布，它已获得另一项价值超过1100万欧元的合同，向rescEU提供MVA-BN®天花疫苗，欧盟（EU）的战略储备。本订单遵循2023年6月授予的初始合同，也将于2024年交付。

The vaccines will be stockpiled in another EU country thus expanding the EU’s capability to respond to biological threats and emergencies in the future by enabling rapid deployment of medical countermeasures to its member states and other countries participating in the EU Civil Protection Mechanism.

这些疫苗将储存在另一个欧盟国家，从而扩大欧盟未来应对生物威胁和紧急情况的能力，以便迅速向其成员国和参与欧盟民事保护机制的其他国家部署医疗对策。

Paul Chaplin, President & CEO of Bavarian Nordic, said: “We are pleased to continue supporting the initiative from EU to build a stockpile of smallpox vaccines across Europe. While our partnership with the European Health Emergency Preparedness and Response Authority (HERA) has focused on mitigating the immediate risk arising from the mpox outbreak in 2022, our recent contracts with rescEU serve to provide a long-term readiness to respond to future health crises.

Paul Chaplin，巴伐利亚北欧公司总裁兼首席执行官，说：“我们很高兴继续支持欧盟在欧洲建立天花疫苗库存的倡议，同时我们与欧洲卫生应急准备和响应局（HERA）合作我们专注于减轻2022年mpox爆发带来的直接风险，我们最近与rescEU签订的合同旨在为应对未来的健康危机提供长期准备。

This obviously secures another order for next year confirming an ongoing demand, but also the transition to stockpiling for future outbreaks, which we see as a growing trend with other countries and organizations.” About the smallpox vaccineMVA-BN or Modified Vaccinia Ankara-Bavarian Nordic (marketed as IMVANEX® in Europe, JYNNEOS® in the U.S.

这显然确保了明年的另一项命令，确认了持续的需求，但也证实了向未来疫情储存的过渡，我们认为这是与其他国家和组织的增长趋势。”关于天花疫苗MVA BN或改良痘苗安卡拉-巴伐利亚北欧（在欧洲销售为IMVANEX®，在美国销售为JYNNEOS®）。

and IMVAMUNE® in Canada) is a non-replicating smallpox vaccine developed in collaboration with the U.S. government to ensure supply of a smallpox vaccine for the entire population, including immunocompromised individuals who are not recommended vaccination with traditional replicating smallpox vaccines.

和IMVAMUNE®在加拿大）是一种非复制型天花疫苗，与美国政府合作开发，以确保为全体人口提供天花疫苗，包括不推荐接种传统复制型天花疫苗的免疫功能低下的个体。

In addition to s.

除了s。

Attachment

附件

2023-09-13-en

2023-09-13-en